Abstract Search

ey0018.5-5 | Advances in clinical practice | ESPEYB18

5.5. Growth curves for children with X-linked hypophosphatemia

Mao Meng , Carpenter Thomas O , Whyte Michael P , Skrinar Alison , Chen Chao-Yin , Martin Javier San , Rogol Alan D

J Clin Endocrinol Metab. 2020 Oct 1;105(10):32433249 Abstract: https://pubmed.ncbi.nlm.nih.gov/32721016/In brief: X-linked hypophosphatemia (XLH) is the most common hereditary form of rickets and osteomalacia. The study used retrospective, pre-burosumab growth data from four different studies and constructed growth charts that demonstrate that the growth rate of children with...

0 shares

ey0021.5-7 | Novel Treatments | ESPEYB21

5.7. Burosumab vs conventional therapy in children with x-linked hypophosphatemia: results of the open-label, phase 3 extension period

Ward Leanne M. , Hogler Wolfgang , Glorieux Francis H. , Portale Anthony A. , Whyte Michael P. , Munns Craig F. , Nilsson Ola , et al.

In brief: This report describes the efficacy and safety of burosumab during the open-label extension period of the original Phase 3 study (weeks 64-88) in 21 children with X-linked hypophosphatemia (XLH) who continued to receive burosumab or crossed over from conventional therapy to burosumab.Commentary: X-linked hypophosphatemia (XLH) is a rare inherited disorder of phosphorus metabolism caused by loss-of-function mutations in the PHEX gene, re...

0 shares

ESPE Yearbook of Paediatric Endocrinology

5.5. Growth curves for children with X-linked hypophosphatemia

5.7. Burosumab vs conventional therapy in children with x-linked hypophosphatemia: results of the open-label, phase 3 extension period

BiosciAbstracts